Bechtel Brett F, Nunez Timothy C, Lyon Jennifer A, Cotton Bryan A, Barrett Tyler W
Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Int J Emerg Med. 2011 Jul 8;4(1):40. doi: 10.1186/1865-1380-4-40.
The acute management of patients on warfarin with spontaneous or traumatic intracranial hemorrhage continues to be debated in the medical literature. The objective of this paper was to conduct a structured review of the medical literature and summarize the advantages and risks of the available treatment options for reversing warfarin anticoagulation in patients who present to the emergency department with acute intracranial hemorrhage.
A structured literature search and review of articles relevant to intracranial hemorrhage and warfarin and treatment in the emergency department was performed. Databases for PubMed, CINAHL, and Cochrane EBM Reviews were electronically searched using keywords covering the concepts of anticoagulation drugs, intracranial hemorrhage (ICH), and treatment. The results generated by the search were limited to English- language articles and reviewed for relevance to our topic. The multiple database searches revealed 586 papers for review for possible inclusion. The final consensus of our comprehensive search strategy was a total of 23 original studies for inclusion in our review.
Warfarin not only increases the risk of but also the severity of ICH by causing hematoma expansion. Prothrombin complex concentrate is statistically significantly faster at correcting the INR compared to fresh frozen plasma transfusions. Recombinant factor VIIa appears to rapidly reverse warfarin's effect on INR; however, this treatment is not FDA-approved and is associated with a 5% thromboembolic event rate. Slow intravenous dosing of vitamin K is recommended in patients with ICH. The 30-day risk for ischemic stroke after discontinuation of warfarin therapy was 3-5%. The risks of not reversing the anticoagulation in ICH generally outweigh the risk of thrombosis in the acute setting.
Increasing numbers of patients are on anticoagulation including warfarin. There is no uniform standard for reversing warfarin in intracranial hemorrhage. Intravenous vitamin K in addition to fresh frozen plasma or prothrombin complex concentrate is recommended be used to reverse warfarin-associated intracranial hemorrhage. No mortality benefit for one treatment regimen over another has been shown. Emergency physicians should know their hospital's available warfarin reversal options and be comfortable administering these treatments to critically ill patients.
华法林治疗的患者发生自发性或创伤性颅内出血时的急性处理方法在医学文献中仍存在争议。本文的目的是对医学文献进行结构化综述,总结急诊科收治的急性颅内出血患者中,用于逆转华法林抗凝作用的现有治疗方案的利弊。
对与颅内出血、华法林及急诊科治疗相关的文章进行结构化文献检索和综述。使用涵盖抗凝药物、颅内出血(ICH)和治疗等概念的关键词,对PubMed、CINAHL和Cochrane循证医学综述数据库进行电子检索。检索结果仅限于英文文章,并对其与我们主题的相关性进行审查。多次数据库检索共筛选出586篇可能纳入综述的文章。我们综合检索策略的最终共识是共纳入23项原始研究。
华法林不仅会增加颅内出血的风险,还会因导致血肿扩大而加重出血严重程度。与输注新鲜冰冻血浆相比,凝血酶原复合物浓缩剂在纠正国际标准化比值(INR)方面在统计学上显著更快。重组因子VIIa似乎能迅速逆转华法林对INR的作用;然而,这种治疗方法未获得美国食品药品监督管理局(FDA)批准,且血栓栓塞事件发生率为5%。对于颅内出血患者,建议缓慢静脉注射维生素K。停用华法林治疗后发生缺血性卒中的30天风险为3% - 5%。在急性情况下,不逆转颅内出血抗凝作用的风险通常超过血栓形成的风险。
包括华法林在内,接受抗凝治疗的患者数量不断增加。颅内出血时逆转华法林抗凝作用尚无统一标准。建议使用静脉注射维生素K,同时联合新鲜冰冻血浆或凝血酶原复合物浓缩剂来逆转与华法林相关的颅内出血。尚未显示一种治疗方案相对于另一种治疗方案有死亡率获益。急诊医生应了解其所在医院可用的华法林逆转方案,并能熟练地对重症患者进行这些治疗。